Reproductive functions decline with the onset of diabetes in female mice. Diabetic mice have smaller uteri with an underdeveloped endometrium, suggesting diminished estrogen-induced growth. We aimed to clarify the changes in the estrous cycle and in insulin-like growth factor 1 (IGF1) expression in the uteri of streptozotocin (STZ)-treated diabetic mice, because IGF1 is one of the main growth factors involved in estrogen-induced uterine growth. ICR female mice were intraperitoneally administered STZ (10 mg/100 g BW), and blood glucose levels were determined. Mice with blood glucose levels > 200 mg/dl were classified as diabetic mice. The onset of diabetes was associated with acyclic estrous cycles. Diabetes was also induced with STZ in ovariectomized mice. Uterine Igf1 mRNA levels were reduced in ovariectomized STZ-treated diabetic mice. Estrogen is known to stimulate Igf1 mRNA expression in the uterus, but estrogen action was abolished in the uteri of STZ-treated diabetic mice. mRNA expressions of estrogen receptor α (ERα) and steroid hormone receptor coactivators (SRC-1/Ncoa1, SRC-2/Ncoa2, SRC-3/Ncoa3 and CBP/p300/Crebbp) were reduced in the uteri of ovariectomized STZ-treated diabetic mice. The present study demonstrates that diabetes induces a decline in female reproductive functions in mice. Igf1 expression in ovariectomized diabetic female mice was decreased, and decreased responsiveness to estrogen in the uteri of diabetic mice is probably associated with a reduction in ERα and steroid receptor coactivator mRNA expression.
Reproductive functions decline with the onset of diabetes in female mice. Diabeticmice have smaller uteri with an underdeveloped endometrium, suggesting diminished estrogen-induced growth. We aimed to clarify the changes in the estrous cycle and in insulin-like growth factor 1 (IGF1) expression in the uteri of streptozotocin (STZ)-treated diabeticmice, because IGF1 is one of the main growth factors involved in estrogen-induced uterine growth. ICR female mice were intraperitoneally administered STZ (10 mg/100 g BW), and blood glucose levels were determined. Mice with blood glucose levels > 200 mg/dl were classified as diabeticmice. The onset of diabetes was associated with acyclic estrous cycles. Diabetes was also induced with STZ in ovariectomized mice. Uterine Igf1 mRNA levels were reduced in ovariectomized STZ-treated diabeticmice. Estrogen is known to stimulate Igf1 mRNA expression in the uterus, but estrogen action was abolished in the uteri of STZ-treated diabeticmice. mRNA expressions of estrogen receptor α (ERα) and steroid hormone receptor coactivators (SRC-1/Ncoa1, SRC-2/Ncoa2, SRC-3/Ncoa3 and CBP/p300/Crebbp) were reduced in the uteri of ovariectomized STZ-treated diabeticmice. The present study demonstrates that diabetes induces a decline in female reproductive functions in mice. Igf1 expression in ovariectomized diabetic female mice was decreased, and decreased responsiveness to estrogen in the uteri of diabeticmice is probably associated with a reduction in ERα and steroid receptor coactivator mRNA expression.
Diabetes mellitus is a complex, heterogeneous disorder with common symptoms being
hyperglycemia and a relative or absolute lack of insulin. Diabetes mellitus is always fatal if
not treated, and even when treated, serious complications such as blindness, kidney disease,
and circulatory or circulatory-based problems may develop. We previously found severe
disorders in pituitary and reproductive functions in streptozotocin (STZ)-induced diabeticmice, and indicated that diabetes mellitus induces disorders in the pituitary-peripheral
target systems [1, 2]. We focused on changes in uterine functions in diabeticmice. STZ was used for
pharmacological induction of diabetes.Diabetic female mice show irregular or acyclic estrous cycles, suggesting a decline in
reproductive function [3]. Diminished pituitary function
in diabeticrats and mice has also been reported [1,2,3,4]. Furthermore, diabetes induces changes in
uterine structures and functions in rats [3], and uteri
of diabeticmice are smaller in size and atrophic, suggesting a diminished response to ovarian
steroid hormones [5]. Interestingly, Garris demonstrated
an increase in lipoapoptotic endometrial epithelial cells in diabetic (db/db)
mice [6].Proliferation of endometrial luminal and glandular epithelial cells is regulated by estrogen,
and proliferation of endometrial stromal cells is regulated by estrogen and progestin [7, 8]. Estrogen and
progestin stimulate the production of growth factors in endometrial cells, which in turn
stimulate DNA synthesis in endometrial cells [9,10,11,12,13]. Insulin-like
growth factor 1 (IGF1) is one of the growth factors that govern the proliferation of
endometrial cells. IGF1 stimulates DNA synthesis in endometrial luminal epithelial cells and
stromal cells through IGF1 receptors (IGF1R) [14,15,16,17,18,19]. IGF1 expression in the uterus is stimulated by
estrogen [16, 20,21,22]. IGF-binding protein-3 (IGFBP3) modulates the actions of IGF1 by binding to the
IGF1 molecule, resulting in obstruction of IGF1 action or prolongation of the half-life of
IGF1 [23, 24].
In endometrial stromal cell cultures, IGFBP3 was shown to inhibit IGF1-induced DNA synthesis
[25, 26]. In
this study, we analyzed three genes of the IGF system, Igf1,
Igfbp3 and Igf1r, to clarify diabetes-related changes in
the uterus.The action of estrogen on Igf1 mRNA expression is mediated through estrogen
receptors (ERs) [27]. Estrogen receptors need several
coactivators or corepressors to exert their transcriptional actions [28, 29]. The steroid receptor
coactivator (SRC) family includes SRC-1/NCoA1, SRC-2/NCoA2/TIF2/GRIP1 and
SRC-3/NCoA3/AIB1/ACTR/RAC3/TRAM-1/pCIP, and is required for transcription of steroid receptors
[30,31,32,33]. cAMP
response element-binding protein (CREB)-binding protein (CBP)/p300 also regulates
transcriptional activities of steroid receptors [31,
34, 35]. We
also studied the effects of diabetes on SRC and CBP/p300 mRNA expression.
Materials and Methods
Animals
Adult female mice of the ICR strain were used. Mice were housed in a
temperature-controlled animal room and were fed a commercial diet (CA-1; CLEA Japan,
Osaka, Japan) and tap water. Vaginal smears were monitored daily to observe estrous
cycles. Animal care and experiments were conducted in accordance with the Guidelines for
Animal Experimentation of Okayama University, Japan.
STZ treatment
Mice were intraperitoneally administered STZ (Sigma-Aldrich, St. Louis, MO, USA) at a
dose of 10 mg/100 g body weight three times every two weeks from 3 months of age. STZ was
dissolved in 0.05 M citric acid (65 mg/ml). Control mice were given vehicle only. In the
other experiment, ovariectomized mice were administered STZ (10 mg/100g body weight) once.
All mice were deprived of food for 16 h before STZ treatment.
Blood glucose measurement
Blood samples were obtained from the tail vein under light ether anesthesia. Blood
glucose level was determined by the glucose oxidase method. Blood glucose levels were
measured every week during experiments. Mice with blood glucose levels above 200 mg/dl
were classified as diabetic.
Histological analysis
Eleven weeks after STZ treatment, uteri were collected from diabeticmice at diestrus,
and uteri were collected from control mice at estrus or diestrus at the age of 5 months.
Uteri were fixed with Bouin's solution. The uteri were embedded in Paraplast, and coronal
uterine serial sections (5 µm thickness) were cut. The sections were stained with
hematoxylin and eosin.
Ovariectomy and estradiol-17β (E2) treatment
Female mice were ovariectomized at 2 months of age under light ether anesthesia. One week
after ovariectomy, mice were treated with STZ as described above. Two weeks after the STZ
treatment, E2 (0.25 or 2.5 µg) or sesame oil was given subcutaneously. Uteri were
collected 48 h after E2 treatment.
cDNA synthesis and real-time PCR
Total RNA was prepared from uteri using a single-step method [36]. Total RNA was reverse-transcribed using ThermoScript Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA) with random 6-mer primers according to the
manufacturer's instructions. Each PCR was performed using primer sets specific for
Igf1, Igfbp3, Igf1r, ERa,
Ncoa1, Ncoa2, Ncoa3, Crebbp
or Rpl19 cDNAs (Table
1). Real-time PCR analysis was conducted using an Applied Biosystems 7300
Real-Time PCR System (Foster City, CA, USA) and SYBR Premix Ex Taq (Takara Bio, Otsu,
Japan). Amplifications were done in 15-µl aliquots according to the manufacturer's
instructions. DNA polymerase was activated by heating at 95 C for 10 sec, followed by 40
cycles of amplification including denaturation at 95 C for 5 sec, and annealing at 60 C
for 31 sec. mRNA levels were normalized to ribosomal protein L19 (Rpl19)
mRNA levels [37].
Table 1.
Sequences of primers used in real-time PCR
Name
Sequence
Length (bp)
ERa
Forward
GGCTGGAGATTCTGATGATTGG
55
Reverse
TTCCCCGGGTGTTCCAT
Igf1
Forward
AAAGCAGCCCCGCTCTATCC
57
Reverse
CTTCTGAGTCTTGGGCATGTCA
Igfbp3
Forward
AAGCACCTACCTCCCCTCCCAA
98
Reverse
TGCTGGGGACAACCTGGCTTTC
Igf1r
Forward
GCTTCTGTGAACCCCGAGTATTT
82
Reverse
TGGTGATCTTCTCTCGAGCTACCT
Ncoa1
Forward
GCTCCAGCAAACTCCACCTACTT
44
Reverse
AATGTTTGCGTTTCCACCTG
Ncoa2
Forward
CCCCGTGGCCTGAGAGCAT
44
Reverse
GAAGTTCCGCAAGGCCAGATACAG
Ncoa3
Forward
GCTTGGGCCACCTTCTAACG
43
Reverse
CTTGAGCTGGGTATGTCTGTCC
Crebbp
Forward
GTCTTTGCCTTTTCGTCAGC
49
Reverse
CCACATACTGCCAGGGTTCT
Rpl19
Forward
CCCGTCAGCAGATCAGGAA
58
Reverse
GTCACAGGCTTGCGGATGA
Statistical analysis
The differences in means among groups were analyzed by analysis of variance followed by
Tukey's test.
Results
Blood glucose levels, estrous cycle and uterine histology
Blood glucose levels in STZ-treated mice started to increase 4 to 5 weeks after the first
STZ injection, while in vehicle-treated control mice, they did not change (Fig. 1). Vehicle-treated control mice continued to show estrous cycle, but most of the
diabeticmice entered a continuous diestrous state, suggesting cessation of ovulation.
Eleven weeks after the STZ treatment, the blood glucose levels remained significantly
higher in the diabeticmice (386 ± 23 mg/dl, n=5) than in the control mice (107 ± 5 mg/dl,
n=5, P<0.0001), and then the uteri of the diabeticmice and control mice were collected
for histological analysis and mRNA measurements.
Fig. 1.
Effect of STZ-treated diabetes on the estrous cycle and blood glucose levels: a
summary of the estrous cycle and blood glucose levels (the number above each line,
mg/dl) of diabetic mice and control mice. Intact female mice were intraperitoneally
administered STZ at a dose of 10 mg/100 g body weight or the vehicle three times
every two weeks at 3 months of age (arrows). Vaginal smears were checked daily (P,
proestrus; E, estrus; D, diestrus), and blood glucose levels were measured every
week.
Effect of STZ-treated diabetes on the estrous cycle and blood glucose levels: a
summary of the estrous cycle and blood glucose levels (the number above each line,
mg/dl) of diabeticmice and control mice. Intact female mice were intraperitoneally
administered STZ at a dose of 10 mg/100 g body weight or the vehicle three times
every two weeks at 3 months of age (arrows). Vaginal smears were checked daily (P,
proestrus; E, estrus; D, diestrus), and blood glucose levels were measured every
week.Histological analysis showed that endometrial epithelia and stroma were less developed in
the diabeticmice than in the control mice (Fig. 2A and
B). The myometrium in the diabeticmice was also less developed. The endometrial
luminal epithelial cell layer was significantly thinner in the diabeticmice than in the
control mice (Fig. 2C and D).
Fig. 2.
Effect of STZ-treated diabetes on uterine morphology. Uteri were obtained from
adult female mice at 5 months of age (eleven weeks after the STZ treatment). (A, C)
Control mice at diestrus; (B, D) diabetic mice at diestrus. G, uterine gland; M,
myometrium. Bar = 250 µm (A, B); bar = 50 µm (C, D).
Effect of STZ-treated diabetes on uterine morphology. Uteri were obtained from
adult female mice at 5 months of age (eleven weeks after the STZ treatment). (A, C)
Control mice at diestrus; (B, D) diabeticmice at diestrus. G, uterine gland; M,
myometrium. Bar = 250 µm (A, B); bar = 50 µm (C, D).
Uterine Igf1, Igfbp3 and Igf1r mRNA expression in STZ-treated diabetic mice
Igf1 mRNA levels in control mice were higher during diestrus than during
estrus (Fig. 3). Igf1 mRNA levels in diabeticmice during diestrus appeared to be
higher than in control mice at estrus, but the difference was not statistically
significant because of the large variation in mRNA levels in the diabeticmice. There were
no differences in Igfbp3 or Igf1r mRNA levels between
control and diabeticmice.
Fig. 3.
Effect of STZ-treated diabetes on uterine Igf1,
Igfbp3 and Igf1r mRNA expressions. Uteri were
obtained from adult female mice at 5 months of age. Igf1,
Igfbp3 and Igf1r mRNA expressions in the uterus
of vehicle-treated control mice (E, estrus; D, diestrus) and STZ-treated diabetic
mice (diestrus) were analyzed by real-time PCR. Each column represents the mean ±
SEM for 5 animals per group. *P<0.05 compared with control mice at estrus.
Effect of STZ-treated diabetes on uterine Igf1,
Igfbp3 and Igf1r mRNA expressions. Uteri were
obtained from adult female mice at 5 months of age. Igf1,
Igfbp3 and Igf1r mRNA expressions in the uterus
of vehicle-treated control mice (E, estrus; D, diestrus) and STZ-treated diabeticmice (diestrus) were analyzed by real-time PCR. Each column represents the mean ±
SEM for 5 animals per group. *P<0.05 compared with control mice at estrus.
Uterine ERa, Ncoa1, Ncoa2, Ncoa3 and Crebbp mRNA expression in the STZ-treated
diabetic mice
ERa mRNA levels in control mice were higher during diestrus than during
estrus (Fig. 4). ERa mRNA levels in diabeticmice during diestrus were higher
than in control mice at diestrus. Ncoa1 mRNA levels in control mice were
higher during diestrus than during estrus. Ncoa1, Ncoa2, Ncoa3 and
Crebb mRNA levels during diestrus in diabeticmice were not different
from those in control mice at diestrus.
Fig. 4.
Effect of STZ-treated diabetes on uterine ERa,
Ncoa1, Ncoa2, Ncoa3 and
Crebbp mRNA expressions. Uteri were obtained from adult female
mice at 5 months of age. ERa, Ncoa1,
Ncoa2, Ncoa3 and Crebbp mRNA
expressions in the uterus of vehicle-treated control mice (E, estrus; D, diestrus)
and STZ-treated diabetic mice (diestrus) were analyzed by real-time PCR. Each column
represents the mean ± SEM for 5 animals per group. *P<0.05; **P<0.01 compared
with control mice at estrus. ###P<0.001 compared with control mice at
diestrus.
Effect of STZ-treated diabetes on uterine ERa,
Ncoa1, Ncoa2, Ncoa3 and
Crebbp mRNA expressions. Uteri were obtained from adult female
mice at 5 months of age. ERa, Ncoa1,
Ncoa2, Ncoa3 and Crebbp mRNA
expressions in the uterus of vehicle-treated control mice (E, estrus; D, diestrus)
and STZ-treated diabeticmice (diestrus) were analyzed by real-time PCR. Each column
represents the mean ± SEM for 5 animals per group. *P<0.05; **P<0.01 compared
with control mice at estrus. ###P<0.001 compared with control mice at
diestrus.
E2 effects on uterine Igf1, Igfbp3 and Igf1r mRNA expression in ovariectomized
STZ-treated diabetic mice
The effect of diabetes on estrogen responsiveness was studied in terms of
Igf1, Igfbp3 and Igf1r mRNA
expression. In control mice, E2 increased Igf1 mRNA levels, and decreased
Igfbp3 and Igf1r mRNA levels, which is in agreement
with our previous studies [18, 25, 38]. In the
diabeticmice, E2 treatment did not affect Igf1, Igf1r
and Igfbp3 mRNA levels, and their levels were lower than in the control
mice given the corresponding treatment (Fig.
5).
Fig. 5.
Effect of E2 on uterine Igf1, Igfbp3 and
Igf1r mRNA expression in ovariectomized STZ-induced diabetic
mice. Ovariectomized STZ-induced diabetic mice were given a single injection of E2
(0.25 or 2.5 µg) or sesame oil as the vehicle. Uteri were collected 48 h after
treatment, Igf1, Igfbp3 and Igf1r
mRNA levels were analyzed by real-time PCR. Each column represents the mean ± SEM
for 5 animals per group. The mRNA levels are shown as relative values compared with
those of control mice given sesame oil. *P<0.05; **P<0.01; ***P<0.001,
****P<0.0001 compared with control mice given sesame oil. #P<0.05;
##P<0.01; ###P<0.001 compared with the control mice
given the corresponding treatment.
Effect of E2 on uterine Igf1, Igfbp3 and
Igf1r mRNA expression in ovariectomized STZ-induced diabeticmice. Ovariectomized STZ-induced diabeticmice were given a single injection of E2
(0.25 or 2.5 µg) or sesame oil as the vehicle. Uteri were collected 48 h after
treatment, Igf1, Igfbp3 and Igf1r
mRNA levels were analyzed by real-time PCR. Each column represents the mean ± SEM
for 5 animals per group. The mRNA levels are shown as relative values compared with
those of control mice given sesame oil. *P<0.05; **P<0.01; ***P<0.001,
****P<0.0001 compared with control mice given sesame oil. #P<0.05;
##P<0.01; ###P<0.001 compared with the control mice
given the corresponding treatment.
E2 effects on uterine ERa, Ncoa1, Ncoa2, Ncoa3 and Crebbp mRNA expression in the
ovariectomized STZ-treated diabetic mice
ERa mRNA levels were lower in the diabeticmice than in the control
mice. E2 treatment did not affect uterine ERa mRNA expression in either
the diabeticmice or the control mice (Fig.
6). Ncoa1, Ncoa2, Ncoa3 and Crebbp mRNA levels were lower in the
diabeticmice than in the control mice. E2 treatment decreased Ncoa1,
Ncoa2 and Crebbp mRNA levels in the control mice, but
did not in the diabeticmice.
Fig. 6.
Effect of E2 on uterine ERa, Ncoa1,
Ncoa2, Ncoa3 and Crebbp mRNA
expression in ovariectomized STZ-induced diabetic mice. Ovariectomized and
STZ-induced diabetic mice were given a single injection of E2 (0.25 or 2.5 µg) or
sesame oil as the vehicle. ERa, Ncoa1,
Ncoa2, Ncoa3 and Crebbp mRNA
levels were analyzed by real-time PCR. Each column represents the mean ± SEM for 5
animals per group. The mRNA levels are shown as relative values compared with those
of control mice given sesame oil. *P<0.05 compared with control mice.
#P<0.05; ##P<0.01; ###P<0.001;
####P<0.0001 compared with the control mice given the corresponding
treatment.
Effect of E2 on uterine ERa, Ncoa1,
Ncoa2, Ncoa3 and Crebbp mRNA
expression in ovariectomized STZ-induced diabeticmice. Ovariectomized and
STZ-induced diabeticmice were given a single injection of E2 (0.25 or 2.5 µg) or
sesame oil as the vehicle. ERa, Ncoa1,
Ncoa2, Ncoa3 and Crebbp mRNA
levels were analyzed by real-time PCR. Each column represents the mean ± SEM for 5
animals per group. The mRNA levels are shown as relative values compared with those
of control mice given sesame oil. *P<0.05 compared with control mice.
#P<0.05; ##P<0.01; ###P<0.001;
####P<0.0001 compared with the control mice given the corresponding
treatment.
Discussion
Diabetes mellitus affects female reproductive functions in humans. Post-menarcheal women
with type 1 diabetes commonly have irregular menstrual cycles, and polycystic ovaries are
frequently observed [39, 40]. Severely altered reproductive functions have been reported in
diabetic mutant (db) and STZ-treated diabetic female mice [3, 41]. The present
study clearly demonstrated that mice with high blood glucose levels induced by STZ treatment
showed no estrous cycle, indicating cessation of ovulation. Diabetic conditions may affect
the hypothalamo-pituitary system that regulates gonadotropin secretion [4, 40]. The uteri
of the STZ-treated diabeticmice were less developed, suggesting reduced estrogen secretion
or diminished responsiveness to estrogen. Thus, there is strong evidence, both from the
present study and previous studies, that female reproductive function is severely affected
by diabetes.The uterus of the diabeticmouse was smaller than that of the control mouse. The
endometrial epithelial and stromal cell layers were thinner in the diabeticmouse. The
myometrial cell layer was also thinner in the diabeticmouse. Therefore, the regulatory
mechanism of uterine growth may be affected under STZ-induced diabetic conditions. The
growth of endometrial epithelial and stromal cells is regulated by growth factors.
Igf1 mRNA was localized in endometrial and myometrial tissues in rat and
mouse uteri [15, 18, 21]. Igf1 mRNA levels
in the uterus changed during the estrous cycle, and its levels at diestrus were higher than
those at estrus, which is consistent with a previous report [42]. IGF1 is one of the growth factors involved in endometrial growth, and
possibly works in a paracrine and autocrine manner [13, 15, 17, 18]. Igf1 mRNA did not
differ between control and diabeticmice, indicating that constitutive production of IGF1
may not be affected by diabetes, which was consistent with a previous study done in
STZ-treated rats [43]. A similar finding was reported
in STZ-treated diabeticmice, although the Igf1 mRNA levels were determined
under human chorionic gonadotropin stimulation [44].
Igfbp3 mRNA levels did not differ between diabeticmice and control mice,
either. The present finding and previous reports may suggest that IGF1 was not a primary
factor responsible for the atrophy of uteri in diabeticmice.Some of the growth factors and related proteins expressed in endometrial epithelial and
stromal cells are regulated by estrogen and progestin. In the uterus, transcription of
Igf1, Igfbp3 and Igf1r is regulated by
estrogen [16, 20, 25, 38]. In the present study, E2 stimulated uterine Igf1 mRNA
expression, and inhibited Igfbp3 and Igf1r mRNA expression
in control mice but did not affect uterine Igf1, Igfbp3
and Igf1r mRNA expression in the diabeticmice. Thus, the responsiveness to
estrogen in terms of IGF1 systems was diminished in diabetic conditions, which was
consistent with a previous report in rats [43]. It is
highly probable that the reduction or lack of response to estrogen in the uterus of diabeticmice is closely associated with atrophy of the uterus.An increase in ERa mRNA levels in diabeticmice was evident, and this was
possibly due to low estrogen levels in diabeticmice, if the regulatory mechanism of ER gene
expression was not affected in the diabeticmice. Estrogen production was decreased in
diabeticrats [45], and blood estrogen levels may be
decreased in diabeticmice. Uterine ER mRNA expression was upregulated when physiological
concentrations of E2 were administered [46] and was
downregulated by higher concentrations [47, 48]. In the present study, ERa mRNA
levels appeared to be decreased by E2 treatment in ovariectomized control mice.A possible reason for the changes in estrogen responsiveness in the uterus of
ovariectomized diabeticmice is the change in estrogen receptor expression. In the uteri of
ovariectomized STZ-treated diabeticmice, ERa mRNA levels were
significantly decreased, which suggests that ER levels were decreased in the uterus,
although ERα levels were not determined in the present study. It is probable that the loss
of estrogen-induced changes in Igf1, Igfbp3 and
Igf1r mRNA expression in the uterus is partly due to a decrease in ER
expression.Nuclear receptors are transcription factors, and their actions are aided by coactivators
including SRCs and CBP/p300. Several nuclear receptor coactivators are expressed in the
uterus [49]. In ovariectomized STZ-treated diabeticmice, mRNA expression of SRCs and CBP/p300 were decreased in the uterus, which may be
associated with the loss of responsiveness to estrogen in diabeticmice.SRC-1 exerts a major role in regulating ER and progesterone receptor (PR) in the uterus
[31]. SRC-1 knockout mice
(SRC-1) are fertile, but their uteri showed less response
in the decidualization [50]. SRC-2 is coexpressed
with SRC-1 in the uterus during pregnancy, and SRC-2 knockout affects the induction of the
decidual reaction under the stimulation of estrogen and progestin [51], and is required for pregnancy [52]. SRC-2 is also involved in the modulation of estrogen, Wnt, and bone
morphogenetic (BMP) growth factor signaling pathways in the uterus [51]. SRC-3 expression is low in the mouse uterus [53, 54], but in the present study,
SRC-3 mRNA was detected. The reason for this discrepancy is not clear. SRC-3 knockout female
mice showed disrupted reproductive functions, delayed puberty and prolonged estrous cycle
[51]. In SRC-3 knockout mice, liver
Igf1 mRNA levels were reduced [55], suggesting the involvement of SRC-3 in Igf1 mRNA expression.
In the present study, SRC-1, SRC-2 and SRC-3 mRNA levels were decreased in the uteri of
STZ-treated diabeticmice, probably leading to the reduced growth of the uterus, although
molecular mechanisms of the interactions of SRCs with ER or PR are not clear.CBP/p300 acts as essential coactivators for many transcription factors [35, 56]. p300
potentiates ERs through the A/B regions of both ERα and ERβ [57]. The decrease in Crebbp mRNA expression may lead to the
diminished transcriptional activation of ER-dependent genes in endometrial cells.SRCs mRNA and CBP/p300 mRNA levels were downregulated by E2 treatment over the course of 48
h, which suggests that these expressions may be associated with E2 and ER levels. On the
contrary, previous reports showed that E2 did not induce significant changes in SRC mRNA
expression in the uterus of ovariectomized rats over the course of 24 h [49]. The discrepancy may be partly due to the difference
in the duration of E2 treatment. The decrease in SRC mRNA expression may be not induced by
diabetic conditions directly. In diabeticmice, the E2-induced changes in SRC mRNA and
CBP/p300 mRNA were not detected. The loss of E2 responsiveness of uterine cells in terms of
SRCs and CBP/p300 expression in diabeticmice may be also responsible for the diminished
growth of uteri.The present study clearly demonstrates diabetes-induced declines in female reproductive
functions: no ovulation and atrophy of uteri. Several changes in gene expression, such as in
the IGF system-related genes, estrogen receptors, and coactivators, were demonstrated in
ovariectomized diabeticmice.
Authors: S L Anzick; J Kononen; R L Walker; D O Azorsa; M M Tanner; X Y Guan; G Sauter; O P Kallioniemi; J M Trent; P S Meltzer Journal: Science Date: 1997-08-15 Impact factor: 47.728
Authors: P S Cooke; D L Buchanan; P Young; T Setiawan; J Brody; K S Korach; J Taylor; D B Lubahn; G R Cunha Journal: Proc Natl Acad Sci U S A Date: 1997-06-10 Impact factor: 11.205
Authors: D Chakravarti; V J LaMorte; M C Nelson; T Nakajima; I G Schulman; H Juguilon; M Montminy; R M Evans Journal: Nature Date: 1996-09-05 Impact factor: 49.962
Authors: Y Kamei; L Xu; T Heinzel; J Torchia; R Kurokawa; B Gloss; S C Lin; R A Heyman; D W Rose; C K Glass; M G Rosenfeld Journal: Cell Date: 1996-05-03 Impact factor: 41.582